Chemo-immunotherapy before surgery for early-onset stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 45 years old.
- You have been diagnosed with adenocarcinoma (a type of cancer) of the stomach or the area where the stomach meets the esophagus.
- Your cancer is at a stage where it can be surgically removed (based on scans and a team discussion).
- Your doctor has confirmed you are fit enough for major abdominal surgery (based on blood tests and overall health).
- You have not had prior chemotherapy, radiation, or immunotherapy for stomach cancer.
- You are not pregnant or breastfeeding, and do not have certain other medical conditions like active autoimmune diseases or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests combining immunotherapy (PD-1 blockers) with chemotherapy before surgery for advanced stomach cancer. The goal is to find the best number of treatment cycles to shrink the tumor and improve surgery results.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
Hear when a new Gastric (Cardia, Body) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.